{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:46:02Z","timestamp":1791726362541,"version":"4.3.4"},"reference-count":62,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>The role of inhaled antifungals for prophylaxis and treatment of invasive fungal pneumonias remains undefined. Herein we summarize recent clinically relevant literature in high-risk groups such as neutropenic hematology patients, including those undergoing stem cell transplant, lung and other solid transplant recipients, and those with sequential mold lung infections secondary to viral pneumonias. Although there are several limitations of the available data, inhaled liposomal amphotericin B administered 12.5 mg twice weekly could be an alternative method of prophylaxis in neutropenic populations at high risk for invasive fungal pneumonia where systemic triazoles are not tolerated. In addition, inhaled amphotericin B has been commonly used as prophylaxis, pre-emptive, or targeted therapy for lung transplant recipients but is considered as a secondary alternative for other solid organ transplant recipients. Inhaled amphotericin B seems promising as prophylaxis in fungal pneumonias secondary to viral pneumonias, influenza, and SARS CoV-2. Data remain limited for inhaled amphotericin for adjunct treatment, but the utility is feasible.<\/jats:p>","DOI":"10.3390\/jof9040464","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T02:09:21Z","timestamp":1681351761000},"page":"464","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease: Promises and Challenges"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3053-9897","authenticated-orcid":false,"given":"Nancy N.","family":"Vuong","sequence":"first","affiliation":[{"name":"Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Hammond","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8051-2940","authenticated-orcid":false,"given":"Dimitrios P.","family":"Kontoyiannis","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3389\/fimmu.2019.01524","article-title":"Pathogenic Fungal Infection in the Lung","volume":"10","author":"Li","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jac\/dkp507","article-title":"Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006","volume":"65","author":"Glasmacher","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"ofab593","DOI":"10.1093\/ofid\/ofab593","article-title":"Prevalence and Healthcare Burden of Fungal Infections in the United States 2018","volume":"9","author":"Rayens","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/QCO.0000000000000504","article-title":"Invasive pulmonary aspergillosis complicating severe influenza: Epidemiology, diagnosis and treatment","volume":"31","author":"Vanderbeke","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e13501","DOI":"10.1111\/tid.13501","article-title":"Invasive pulmonary aspergillosis associated with COVID-19 in a kidney transplant recipient","volume":"23","author":"Trujillo","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s13054-021-03728-w","article-title":"Inhaled liposomal amphotericin-B as a prophylactic treatment for COVID-19-associated pulmonary aspergillosis\/aspergillus tracheobronchitis","volume":"25","author":"Rutsaert","year":"2021","journal-title":"Crit. Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S2352-3026(21)00232-5","article-title":"Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs","volume":"9","author":"Bruggemann","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/DHPS.S6321","article-title":"Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections","volume":"2","author":"Neofytos","year":"2010","journal-title":"Drug Healthc. Patient Saf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/01.TP.0000101516.08327.A9","article-title":"Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients","volume":"77","author":"Drew","year":"2004","journal-title":"Transplantation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: A randomized, placebo-controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: Summary of the updated recommendations from the European Conference on Infections in Leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","article-title":"Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"97","author":"Mellinghoff","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e13544","DOI":"10.1111\/ctr.13544","article-title":"Invasive Aspergillosis in solid-organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Husain","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.healun.2016.01.007","article-title":"The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary","volume":"35","author":"Husain","year":"2016","journal-title":"J. Heart Lung Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e13630","DOI":"10.1111\/ctr.13630","article-title":"Antifungal prophylaxis in lung transplant: A survey of United States\u2019 transplant centers","volume":"33","author":"Pennington","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1100\/2011\/865239","article-title":"Tracheobronchial manifestations of Aspergillus infections","volume":"11","author":"Krenke","year":"2011","journal-title":"Sci. World J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/tri.12679","article-title":"10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation","volume":"29","author":"Peghin","year":"2016","journal-title":"Transpl. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/ajt.12691","article-title":"Epidemiology of invasive mold infections in lung transplant recipients","volume":"14","author":"Doligalski","year":"2014","journal-title":"Am. J. Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1016\/j.transproceed.2008.09.020","article-title":"Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation","volume":"40","author":"Borro","year":"2008","journal-title":"Transplant. Proc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11908-013-0380-y","article-title":"Anti-Aspergillus Prophylaxis in Lung Transplantation: A Systematic Review and Meta-analysis","volume":"15","author":"Bhaskaran","year":"2013","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/ctr.12854","article-title":"Is universal antifungal prophylaxis mandatory in adults after lung transplantation? A review and meta-analysis of observational studies","volume":"30","author":"Pilarczyk","year":"2016","journal-title":"Clin. Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1399-3062.2006.00125.x","article-title":"Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"8","author":"Alexander","year":"2006","journal-title":"Transpl. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000327802","article-title":"Prophylactic application of nebulized liposomal amphotericin B in hematologic patients with neutropenia","volume":"34","author":"Holler","year":"2011","journal-title":"Onkologie"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1399-3062.2011.00661.x","article-title":"Low incidence of invasive aspergillosis in allogeneic stem cell transplant recipients receiving amphotericin B inhalation prophylaxis","volume":"14","author":"Nihtinen","year":"2012","journal-title":"Transpl. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijantimicag.2015.02.023","article-title":"Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life","volume":"46","author":"Chong","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1034\/j.1399-3062.2002.t01-2-02002.x","article-title":"The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants","volume":"4","author":"Minari","year":"2002","journal-title":"Transpl. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.healun.2009.11.603","article-title":"Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation","volume":"29","author":"Monforte","year":"2010","journal-title":"J. Heart Lung Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/phar.1309","article-title":"Aerosolized amphotericin B lipid complex as adjunctive treatment for fungal lung infection in patients with cancer-related immunosuppression and recipients of hematopoietic stem cell transplantation","volume":"33","author":"Safdar","year":"2013","journal-title":"Pharmacotherapy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11046-019-00331-0","article-title":"Aerosolized Lipid Amphotericin B for Complementary Therapy and\/or Secondary Prophylaxis in Patients with Invasive Pulmonary Aspergillosis: A Single-Center Experience","volume":"184","author":"Venanzi","year":"2019","journal-title":"Mycopathologia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13054-021-03874-1","article-title":"Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: A European multicenter comparative cohort study","volume":"26","author":"Rouze","year":"2022","journal-title":"Crit. Care"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2213-2600(20)30237-X","article-title":"Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19","volume":"8","author":"Alanio","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.chest.2020.06.010","article-title":"Influenza-Associated Aspergillosis: Nationwide Trends, Predictors and Outcomes From 2005 to 2014","volume":"158","author":"Sharma","year":"2020","journal-title":"Chest"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","article-title":"Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: A retrospective cohort study","volume":"6","author":"Schauwvlieghe","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/cid\/ciaa007","article-title":"High Rates of Influenza-Associated Invasive Pulmonary Aspergillosis May Not Be Universal: A Retrospective Cohort Study from Alberta, Canada","volume":"71","author":"Schwartz","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/cid\/ciz568","article-title":"Reply to Verweij et al","volume":"70","author":"Uyeki","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1093\/cid\/ciaa010","article-title":"Influenza-Associated Pulmonary Aspergillosis: A Local or Global Lethal Combination?","volume":"71","author":"Rijnders","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_39","first-page":"1631","article-title":"Navigating the Uncertainties of COVID-19-Associated Aspergillosis: A Comparison With Influenza-Associated Aspergillosis","volume":"224","author":"Lamoth","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Egger, M., Bussini, L., Hoenigl, M., and Bartoletti, M. (2022). Prevalence of COVID-19-Associated Pulmonary Aspergillosis: Critical Review and Conclusions. J. Fungi, 8.","DOI":"10.3390\/jof8040390"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100971","DOI":"10.1016\/j.mycmed.2020.100971","article-title":"Invasive fungal diseases during COVID-19: We should be prepared","volume":"30","author":"Gangneux","year":"2020","journal-title":"J. Mycol. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/thx.54.11.1047","article-title":"Successful treatment of post-influenza pseudomembranous necrotising bronchial aspergillosis with liposomal amphotericin, inhaled amphotericin B, gamma interferon and GM-CSF","volume":"54","author":"Boots","year":"1999","journal-title":"Thorax"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijid.2016.11.419","article-title":"Pulmonary aspergillosis treated with inhaled amphotericin B","volume":"54","author":"Zhou","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.chest.2021.08.045","article-title":"A 67-Year-Old Male Patient With COVID-19 With Worsening Respiratory Function and Acute Kidney Failure","volume":"161","author":"Melchers","year":"2022","journal-title":"Chest"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1164\/rccm.202005-1883ED","article-title":"Invasive Aspergillus Tracheobronchitis Emerging as a Highly Lethal Complication of Severe Influenza","volume":"202","author":"Wauters","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13613-020-00686-4","article-title":"COVID-19-associated invasive pulmonary aspergillosis","volume":"10","author":"Rutsaert","year":"2020","journal-title":"Ann. Intensive Care"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e0696","DOI":"10.1097\/CCE.0000000000000696","article-title":"Nebulized Amphotericin B in Mechanically Ventilated COVID-19 Patients to Prevent Invasive Pulmonary Aspergillosis: A Retrospective Cohort Study","volume":"4","author":"Melchers","year":"2022","journal-title":"Crit. Care Explor."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00134-021-06603-y","article-title":"Inhaled amphotericin B lipid complex for prophylaxis against COVID-19-associated invasive pulmonary aspergillosis","volume":"48","author":"Soriano","year":"2022","journal-title":"Intensive Care Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s00134-020-06091-6","article-title":"Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: An expert opinion","volume":"46","author":"Verweij","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Brunet, K., Martellosio, J.P., Tewes, F., Marchand, S., and Rammaert, B. (2022). Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14030641"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Murray, A., Cass, L., Ito, K., Pagani, N., Armstrong-James, D., Dalal, P., Reed, A., and Strong, P. (2020). PC945, a Novel Inhaled Antifungal Agent, for the Treatment of Respiratory Fungal Infections. J. Fungi, 6.","DOI":"10.3390\/jof6040373"},{"key":"ref_53","unstructured":"Pulmocide Ltd. (2021). Safety and Efficacy of PC945 in Combination with Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis, Pulmocide Ltd."},{"key":"ref_54","unstructured":"Pulmocide Ltd. (2021). PC945 Prophylaxis or Pre-Emptive Therapy against Pulmonary Aspergillosis in Lung Transplant Recipients, Pulmocide Ltd."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4274\/tjh.2018.0007","article-title":"Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies","volume":"35","author":"Gamaletsou","year":"2018","journal-title":"Turk. J. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3389\/fmicb.2017.01024","article-title":"Azole Resistance in Aspergillus fumigatus: A Consequence of Antifungal Use in Agriculture?","volume":"8","author":"Berger","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/jcph.437","article-title":"Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib","volume":"55","author":"Suttle","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1161\/CIR.0000000000001056","article-title":"Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association","volume":"145","author":"Beavers","year":"2022","journal-title":"Circulation"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14728214.2021.2009800","article-title":"Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia","volume":"27","author":"Montesinos","year":"2022","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/jac\/dkp464","article-title":"Safety of triazole antifungal drugs in patients with cancer","volume":"65","author":"Cronin","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2165\/00003088-200544100-00005","article-title":"Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol","volume":"44","author":"Swaisland","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/cid\/ciab1070","article-title":"Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective","volume":"75","author":"Lamoth","year":"2022","journal-title":"Clin. Infect. Dis."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/9\/4\/464\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:14:34Z","timestamp":1760123674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/9\/4\/464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":62,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["jof9040464"],"URL":"https:\/\/doi.org\/10.3390\/jof9040464","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]}}}